We are committed to serving the best interests of our shareholders.

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary TESARO Secures $500 Million Non-Dilutive Term Loan Financing
WALTHAM, Mass. , Nov. 21, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology focused biopharmaceutical company, announced today that it has entered into a definitive term loan agreement with BIOPHARMA CREDIT PLC and BIOPHARMA CREDIT INVESTMENTS IV SUB LP, investment funds managed by
View HTML
Toggle Summary TESARO’s Mary Lynne Hedley and Lonnie Moulder Named EY National Entrepreneurs of the Year®
WALTHAM, Mass. , Nov. 20, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. , an oncology-focused biopharmaceutical company, is proud to announce that co-founders Lonnie Moulder , CEO, and Mary Lynne Hedley , Ph.D., President and COO, have been named EY Entrepreneurs of the Year® 2017 Overall National Award
View HTML
Toggle Summary TESARO Announces European Commission Approval of ZEJULA® for Women With Recurrent Ovarian Cancer
ZEJULA is the first PARP inhibitor approved in Europe for women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker status Approval supported by robust data from a randomized, well-controlled Phase 3 trial Only PARPi to offer once-daily, oral dosing to enable convenient
View HTML
Toggle Summary TESARO Announces Third-Quarter 2017 Operating Results
ZEJULA ® was the most prescribed PARP inhibitor in U.S. with Q3 net sales of $39.4 million Positive CHMP opinion issued for ZEJULA in E.U.; commercial launch anticipated to begin by year-end Expansion of niraparib development program underway for multiple tumor types VARUBI ® IV approved by U.S.
View HTML
Toggle Summary TESARO Announces U.S. FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy
VARUBI injectable emulsion features a ready-to-use, single-dose vial for intravenous administration Availability of new formulation offers healthcare providers the flexibility to choose oral or IV administration VARUBI provides enhanced control of delayed CINV as part of an antiemetic regimen,
View HTML
Toggle Summary TESARO to Announce Third-Quarter 2017 Financial Results on November 7, 2017
WALTHAM, Mass. , Oct. 24, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its third-quarter 2017 financial results on Tuesday, November 7, 2017 , after the close of the U.S. financial markets. TESARO’s senior management team will host a conference call and live audio webcast at
View HTML
Toggle Summary TESARO Announces Participation at Two Investor Conferences
WALTHAM, Mass. , Oct. 23, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are: The Credit Suisse 26 th Annual Healthcare Conference at The Phoenician in
View HTML
Toggle Summary The Foundation for Women’s Cancer and TESARO Announce 2nd Year of Partnership Supporting the National Race to End Women’s Cancer
CHICAGO and WALTHAM, Mass. , Oct. 18, 2017 (GLOBE NEWSWIRE) -- The Foundation for Women’s Cancer (FWC), the official foundation of the Society of Gynecologic Oncology , and TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the continuation of their
View HTML
Toggle Summary TESARO Expands Our Way Forward Program for the Ovarian Cancer Community and Partners With Olympic Gymnast Shannon Miller
 Gold-Medal Gymnast and Ovarian Cancer Survivor Shannon Miller Will Broaden Awareness About Advanced Ovarian Cancer as a Continuation of the Our Way Forward Program WALTHAM, Mass. , Sept. 28, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company,
View HTML
Toggle Summary TESARO Receives Positive CHMP Opinion for ZEJULA®
ZUG, Switzerland , Sept. 15, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the Company’s marketing
View HTML